Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The 2018 Zülch Prize honours research into autoimmunity in neurological diseases. Angela Vincent shares the award with Jerome Posner and Josep Dalmau.

Cancer, infections and other still undescribed factors can trigger the body’s immune system. In some patients’ this results in an autoimmune attack against healthy tissue such as cells of the nervous system that results in a variety of neurological syndromes. This can lead to deficits such as memory loss, seizures, movement disorders, muscle weakness, and psychosis.

The Gertrud Reemtsma Foundation has now paid tribute to Jerome Posner, Angela Vincent and Josep Dalmau for their research into how autoimmunity produces these neurological disorders. Their work has been pivotal in ensuring that many of these disorders are now recognised and patients promptly treated offering the best opportunity for neurologic improvement. In recognition of their outstanding achievement, the researchers have been awarded the Gertrud Reemtsma Foundation's K. J. Zülch Prize worth 50,000 euro. The award ceremony will take place in Cologne, Germany on 21 September 2018.

The prize winners have made crucial advances in research into these immune diseases by providing detailed clinical descriptions and through the development of simple diagnostic tests that allowed practitioners to quickly recognize, diagnose, and treat these patients. Their work has also provided insights into how cancers and other triggers such as viral infections initiate the autoimmune attack. This has opened new avenues to research into how to prevent and optimally treat these diseases. 

Professor Angela Vincent initially studied autoimmune diseases of the peripheral nervous system in which signal transmission between nerves and muscles are impaired. This led her to the then revolutionary insight that certain antibodies can also attack the central nervous system.  She subsequently developed the diagnostic methods widely used in hospitals today.

Read more

Similar stories

Capturing immune cells that colonise the brain to prevent disease progression in multiple sclerosis

Clinical Neurology Research

Researchers have revealed a disease-causing population of immune cells, which travel to the brain in patients with multiple sclerosis. They demonstrate how to trap these cells in the blood, which means they can be targeted to prevent disease progression.

Two neurologists awarded MRC Senior Clinical Fellowships

Clinical Neurology Research

Two of our Associate Professors, Sarosh Irani and George Tofaris, have been awarded MRC Senior Clinical Fellowships.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Low-cost ventilator wins at E&T Innovation Awards

Anaesthetics Award Coronavirus

The OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.